DiaMedica-Logo.png
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
April 30, 2019 16:58 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
March 19, 2019 16:30 ET | DiaMedica Therapeutics Inc.
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute ischemic stroke Phase II...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
March 18, 2019 13:56 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March...
DiaMedica-Logo.png
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
March 12, 2019 13:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz...
DiaMedica-Logo.png
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
February 14, 2019 08:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
January 22, 2019 07:45 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled  “Human Tissue Kallikrein In The Treatment Of Acute Ischemic...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
January 09, 2019 17:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 09, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) (TSX-V: DMA), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily...
DiaMedica-Logo.png
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 10:41 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica-Logo.png
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 07:30 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica-Logo.png
DiaMedica Closes Public Offering in the United States
December 11, 2018 17:30 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”) (NASDAQ:DMAC; TSXV:DMA), a clinical stage biopharmaceutical company, announced today that it...